When producing gene therapies, circular plasmids containing therapeutic DNA , an outer capsid shell, and proteins required for virus assembly are inserted into host cells. Manufacturers often face difficulties creating consistency in gene therapy products due to incomplete transfer of genetic material.  In this article from Cell & Gene, Kymanox experts discuss challenges to manufacturing safe and effective gene therapies related to the purification process of viral vectors.